Sign In

Murray Robinson

Co-Founder Rubik Therapeutics

Murray Robinson is a seasoned professional with 30 years of experience in Biotech Cancer R&D, focusing on Drug Discovery, Development, Translational Medicine, and Computational Analytics.

He holds a Doctor of Philosophy (PhD) in Molecular Biology from the prestigious California Institute of Technology, a renowned institution known for its scientific advancements.

Throughout his career, Murray has held key roles at notable organizations such as Amgen, AVEO Pharmaceuticals, and Molquant, where he contributed significantly to the field of oncology.

With a rich educational background that includes graduate work in Molecular Biology from The Johns Hopkins University and a Bachelor of Arts (BA) in Biochemistry/Cell Biology from the University of California, San Diego, Murray possesses a strong foundation in the life sciences.

Currently, Murray Robinson serves as the Co-founder of Rubik Therapeutics, a company dedicated to developing synthetic immune therapy for oncology, showcasing his entrepreneurial spirit and leadership in the biotech industry.

His previous roles include being the President of Molquant, Inc., Chief Scientific Officer at Medisix Therapeutics Pte Ltd., and various high-level positions at AVEO Oncology and Amgen, where he spearheaded Translational Medicine, Cancer Biology initiatives, and R&D efforts.

Murray's expertise and contributions in the biotech sector have made him a prominent figure in the field, recognized for his strategic vision, scientific acumen, and commitment to advancing cancer research and therapeutic development.

Murray Robinson
Add to my network

Location

Boston, Massachusetts, United States